Grapefruit juice could change how depression drug works
NCT ID NCT06726382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested how grapefruit juice and the HIV drug cobicistat affect levels of esketamine, a depression treatment, in 12 healthy volunteers. Participants received esketamine as a nasal spray or oral liquid, with or without these substances. Researchers measured drug levels in the blood over 24 hours to see if these interactions matter.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Esketamine (nasal spray and oral solution), cobicistat, grapefruit juice
What this could lead to
If successful, this could help doctors understand how to adjust esketamine doses when taken with common substances like grapefruit juice, potentially making treatment more affordable or effective.
What could go wrong
This is a very small, early-phase study in healthy volunteers, not patients. It only measures drug levels, not actual treatment outcomes, so results may not apply to real-world depression care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG INTERACTIONS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Pharmacology
Helsinki, Finland